RESEARCH

Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials

OPEN ACCESS

Seung-Kwon Myung *senior scientist*^{1,2}, Woong Ju *associate professor*³, Belong Cho *professor*¹, Seung-Won Oh *assistant professor*⁴, Sang Min Park *associate professor*¹, Bon-Kwon Koo *associate professor*⁵, Byung-Joo Park *professor*⁶, for the Korean Meta-Analysis (KORMA) Study Group

¹Department of Family Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; ²Carcinogenesis Research Branch and Department of Family Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea; ³Department of Obstetrics and Gynecology and Medical Research Institute, College of Medicine, Ewha Womans University, Seoul, Republic of Korea; ⁴Healthcare Research Institute and Department of Family Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Republic of Korea; ⁵Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; ⁶Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

Abstract

Objective To assess the efficacy of vitamin and antioxidant supplements in the prevention of cardiovascular diseases.

Design Meta-analysis of randomised controlled trials.

Data sources and study selection PubMed, EMBASE, the Cochrane Library, Scopus, CINAHL, and ClinicalTrials.gov searched in June and November 2012. Two authors independently reviewed and selected eligible randomised controlled trials, based on predetermined selection criteria.

Results Out of 2240 articles retrieved from databases and relevant bibliographies, 50 randomised controlled trials with 294 478 participants (156 663 in intervention groups and 137 815 in control groups) were included in the final analyses. In a fixed effect meta-analysis of the 50 trials, supplementation with vitamins and antioxidants was not associated with reductions in the risk of major cardiovascular events (relative risk 1.00, 95% confidence interval 0.98 to 1.02; $I^2=42\%$). Overall, there was no beneficial effect of these supplements in the subgroup meta-analyses by type of prevention, type of vitamins and antioxidants, type of cardiovascular outcomes, study design, methodological quality, duration of treatment, funding source, provider of supplements, type of control, number of participants in each trial, and supplements given singly or in combination with other supplements. Among the subgroup meta-analyses by type of cardiovascular outcomes, vitamin and antioxidant supplementation was associated with a marginally increased risk of

angina pectoris, while low dose vitamin B₆ supplementation was associated with a slightly decreased risk of major cardiovascular events. Those beneficial or harmful effects disappeared in subgroup meta-analysis of high quality randomised controlled trials within each category. Also, even though supplementation with vitamin B₆ was associated with a decreased risk of cardiovascular death in high quality trials, and vitamin E supplementation with a decreased risk of myocardial infarction, those beneficial effects were seen only in randomised controlled trials in which the supplements were supplied by the pharmaceutical industry.

Conclusion There is no evidence to support the use of vitamin and antioxidant supplements for prevention of cardiovascular diseases.

Introduction

Cardiovascular diseases are the leading causes of deaths and disability worldwide.¹ Over the past few decades, observational epidemiological studies have reported that intake of fruit and vegetables rich in various vitamins and antioxidants reduce the risk.² It has been estimated that if an individual increases fruit and vegetable intake up to 600 g daily, the worldwide burden of disease could be reduced by 31% for ischaemic heart disease and 19 % for ischaemic stroke.³ Unlike the evidence for fruit and vegetables, however, many randomised controlled trials have reported inconsistent findings regarding the efficacy of

Correspondence to: B Cho, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Republic of Korea belong@snu.ac.kr, and S-K Myung, 323 Ilsan-ro, Ilsandong-gu, Gyeonggi-do, 410-769, Republic of Korea msk@ncc.re.kr

Extra material supplied by the author (see <http://www.bmj.com/content/346/bmj.f10?tab=related#webextra>)

Appendix 1: Full details of 50 included trials

vitamin and antioxidant supplementation on cardiovascular diseases.⁴

Several meta-analyses have reported conflicting evidence from randomised controlled trials. In 2003, a meta-analysis of 12 trials indicated that vitamin E supplements did not provide benefit in cardiovascular death or cerebrovascular events.⁵ Instead, it showed that β carotene supplementation led to a small increase in all cause mortality and cardiovascular death. In 2006, Flores-Mateo et al reported that the use of supplements containing selenium did not reduce the risk of coronary heart disease in the meta-analysis of six trials.⁶ More recently, however, Lee et al found that folic acid supplementation with B vitamins had potential small benefits in the prevention of stroke,⁷ and Qin et al indicated that folic acid treatment decreased the risk of cardiovascular disease by 15% in patients with end stage renal disease or advanced chronic kidney disease.⁸ Even though several meta-analyses of randomised controlled trials have been published regarding the efficacy of vitamins and antioxidant supplements on cardiovascular diseases, they involved individual vitamins or antioxidants, and there was no published comprehensive meta-analysis that reviewed this topic all together in one report. To the best of our knowledge, no meta-analyses have performed subgroup analyses by important factors such as methodological quality or funding source.

We investigated the efficacy of vitamin and antioxidant supplements on cardiovascular diseases through a comprehensive meta-analysis of randomised controlled trials by various factors such as by type of prevention (primary v secondary), type of vitamins and antioxidants, dose of supplement, type of cardiovascular outcomes, study design, methodological quality (high v low), duration of treatment (<5 years v ≥ 5 years), funding source (independent organisation v pharmaceutical industry), provider of supplements (pharmaceutical industry v not pharmaceutical industry), type of control (placebo v no placebo), number of participants in each trial (<10 000 v ≥ 10 000), and supplements given singly or in combination with other vitamin or antioxidant supplements.

Methods

Literature search

We searched PubMed, Embase, the Cochrane Library, Scopus, CINAHL, and ClinicalTrials.gov in June and November 2012 using common keywords related to vitamin or antioxidant supplements and cardiovascular diseases. The keywords were as follows: “vitamin supplement,” “antioxidant supplement,” “vitamin A supplement,” “vitamin B₆ supplement,” “vitamin B₁₂ supplement,” “folic acid supplement,” “vitamin C supplement,” “vitamin D supplement,” “vitamin E supplement,” “selenium supplement,” “beta-carotene supplement,” “lycopene supplement,” or “isoflavone supplement,”; and “cardiovascular disease,” “angina,” “acute myocardial infarction,” “transient ischemic attack,” or “stroke.” We also reviewed the bibliographies of relevant articles to locate additional publications. The language of publication was not restricted.

Selection criteria

To be included randomised controlled trials had to report the efficacy of vitamin or antioxidant supplements for the prevention of cardiovascular diseases and follow participants for at least six months. If data were duplicated or shared in more than one study, we included the first published or more comprehensive study in the analysis.

Selection of relevant studies

Based on the predetermined selection criteria, two of the authors (S-KM, WJ) independently selected all trials retrieved from the databases and bibliographies. Disagreements were resolved by discussion or in consultation with a third author (S-WO).

Assessment of methodological quality

We assessed the methodological quality of included trials with the Jadad scale.⁹ Its score ranges from 0 (very poor) to 5 (rigorous). The five point quality scale consists of points for randomisation (described as randomised, 1 point; table of random numbers or computer generated randomisation, additional 1 point), double blind (described as double blind, 1 point; use masking such as identical placebo, additional 1 point), and follow-up (state the numbers and reasons for withdrawal in each group; 1 point) in the report of each trial. All trials were classified into two groups, those with a score of ≤ 4 or versus 5 because the mean score for the 47 trials assessed in the current study (the full text for three trials was not available) was 4.3, and then subgroup meta-analyses were performed.

Main and subgroup analyses

We investigated the association between vitamin or antioxidants supplementation and major cardiovascular events. Major cardiovascular events included cardiovascular death, fatal or non-fatal myocardial infarction, angina, sudden cardiac death, fatal or non-fatal stroke, and transient ischaemic attack. We also performed subgroup meta-analyses by type of prevention (primary v secondary: in this study, trials involving healthy populations or patients with any specific disease except for cardiovascular disease were classified as primary prevention trials, and trials involving patients with cardiovascular disease were classified as secondary prevention trials), type of supplement by quality and dose (each supplement, vitamins only, antioxidants only, or antioxidants excluding vitamins), type of outcome (cardiovascular death, angina, fatal or non-fatal myocardial infarction, stroke, or transient ischaemic attack), type of outcome in each supplement, type of study design (randomised, double blind, placebo controlled trial v open label, randomised controlled trial), methodological quality (high v low), duration of treatment (<5 years v ≥ 5 years), funding source (pharmaceutical industry v independent organisation), provider of supplements (pharmaceutical industry v not pharmaceutical industry), type of control (placebo v no placebo), number of participants (≥ 10 000 v <10 000), and supplements given singly or in combination with other vitamin or antioxidant supplements by quality.

Statistical analysis

We calculated the relative risks with 95% confidence intervals by using crude 2x2 tables on the basis of intention to treat analysis, whenever possible, from the original publications. For the test of heterogeneity, we used Higgins I^2 , which measures the percentage of total variation across trials.¹⁰ I^2 was calculated as follows:

$$I^2 = 100\% \times (Q - df)/Q,$$

where Q is Cochran's heterogeneity statistic and df indicates the degrees of freedom. Negative values of I^2 are set to zero. I^2 ranges from 0% (no observed heterogeneity) to 100% (maximal heterogeneity).

To calculate pooled relative risks with 95% confidence intervals, we used both the fixed effects and random effects models. An I^2 value >50% was considered as substantial heterogeneity.

When there was no substantial heterogeneity, we reported the pooled estimate calculated from the fixed effects model. When there was substantial heterogeneity, we reported the pooled estimate calculated from the random effects model.

We assessed publication bias with Begg's funnel plot and Egger's test. If publication bias exists, the Begg's funnel plot is asymmetric or the Egger's test P value is <0.05 . We used Stata SE version 10.0 software (StataCorp, College Station, TX) for all the statistical analyses.

Results

By searching databases (PubMed, Embase, the Cochrane Library, Scopus, CINAHL, and ClinicalTrials.gov) and hand searching relevant bibliographies, we identified 2240 articles (fig 1). After excluding 573 duplicated articles, two of authors independently reviewed and excluded 1593 articles that did not satisfy the predetermined selection criteria based on each article's title and abstract. We reviewed the full texts of the 74 remaining articles and excluded 24 articles (16 were identical trials within the same population; five were not related to the subject of this study; two were replies or comments; and one reported insufficient data). A total of 50¹¹⁻⁶⁰ trials were included in the final analysis. The full details of all included trials are in appendix 1. The 50 trials included 294 478 participants with 156 663 in intervention groups and 137 815 in control groups. In the trials reporting age, the mean age of the participants ranged from 49 to 82. The year of publication of the included trials ranged between 1989 and 2012, spanning 23 years. Twelve trials were conducted in the United States, four in the United Kingdom, three in Finland, three in France, three in Italy, two in Canada, two in Israel, two in Australia, two in China, two in Germany, two in Norway, one in Sweden, one in Switzerland, one in the Netherlands, one in US/Canada, one in US/Canada/Scotland, one in Germany/the Netherlands, one in Canada/US, one in 13 countries, and one in 20 countries. The range of supplementation and follow-up periods was 6 months to 12 years. The number of participants ranged from 61 to 39 876.

Among the 50 trials, 30 were primary prevention trials (general populations, smokers and workers exposed to asbestos, patients with oesophageal dysplasia, male physicians, patients with non-melanoma skin cancer, postmenopausal women, patients undergoing chronic haemodialysis, patients with end stage renal disease, ambulatory elderly women with vitamin D insufficiency, patients with chronic renal failure, older people with femoral neck fractures, patients with diabetes mellitus, elderly women with a low serum 25-hydroxyvitamin D concentration, health professionals, people with a high fasting plasma total homocysteine concentration, or kidney transplant recipients), and 20 were secondary prevention trials (patients with cardiovascular disease, coronary heart disease, acute myocardial infarction, unstable angina, transient ischaemic attack, stroke, angiographically proved coronary atherosclerosis, vascular disease, or aortic valve stenosis).

Forty five trials were randomised, double blind, placebo controlled trials, and five were open label, randomised controlled trials. All vitamin or antioxidant supplements and placebos were administered orally either singly or in combination with other vitamin or antioxidant supplements.

The dose regimens used in each trial were as follows: vitamin A (10 000 or 25 000 IU daily), vitamin B₆ (3, 6, 10, 12.5, 25, 40, 48, 50, or 100 mg daily; 20 mg three times weekly), vitamin B₁₂ (0.4, 0.5, 1, or 2 mg daily; 6, 18, 20, 60, or 400 µg daily; 50 µg three times weekly), vitamin C (60, 120, 180, 250, 500, or

1000 mg daily), vitamin D (800 or 1000 IU daily; 200 IU twice daily; 400 IU twice daily; 300 IU daily and 100 IU daily; 100 000 IU every four months), vitamin E (60, 200, 400, 600, 800 IU daily; 400 or 600 IU alternate day; 400 IU twice daily; 30, 50, 300, 600 mg daily), β carotene (6, 15, 20, 25, 30, or 50 mg daily; 50 mg alternate day), folic acid (560 or 800 µg daily; 0.5, 0.8, 1, 1.2, 2, 2.5, 5, 15, or 40 mg daily; 5 mg three times weekly), and selenium (50, 75, 100, 122, or 122 µg daily).

Thirty nine trials used vitamin supplements only, and 22 trials used antioxidant supplements only. The additional nutritional supplements or drugs used in each trial were aspirin (325 mg daily); coenzyme Q10 (100 mg daily); calcium (93 mg daily) with or without hormone replacement therapy; application of a sun protection factor 15+ sunscreen; ramipril (angiotensin converting enzyme inhibitor; with or without aspirin (100 mg daily); zinc (20 mg daily); multivitamins and minerals; calcium carbonate (500 mg twice daily); calcium (1000 mg daily); calcium citrate (1000 mg daily); omega 3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid at a ratio of 2:1). The main outcomes used in each trial were fatal or non-fatal acute myocardial infarction, unstable angina, coronary heart disease, ischaemic heart disease, major coronary events, cardiovascular death, sudden death, transient ischaemic stroke, stroke, and cardiovascular disease.

Out of 47 trials reporting funding source, five were funded by pharmaceutical companies and 42 were funded mainly by public or governmental organisations or independent scientific foundations. Also, in 29 trials, vitamin or antioxidant supplements were provided at no cost from the pharmaceutical industry, while 18 trials paid for them or did not mention whether the pharmaceutical industry charged for them.

In the fixed effects meta-analysis of all 50 trials, use of vitamin or antioxidant supplements was not associated with reduced risks of major cardiovascular events (relative risk 1.00; 95% confidence interval 0.98 to 1.02; $I^2=42\%$) (fig 2). Overall, the effect sizes of the smaller randomised controlled trials tend to be less than 1.0, while the effect sizes of the larger ones tend to be null. In the 48 selected trials, the Begg's funnel plot was symmetrical, and P for bias was 0.11 in the Egger's test (two^{12 22} of the 50 trials were not included because of "zero" cells in the 2x2 table) (the Begg's funnel plot is not shown in the figure).

Based on the Jadad scales, the mean score for the 47 trials assessed was 4.3, ranging from 2 to 5 (table 1).

Tables 2-4 show the efficacy of vitamin or antioxidant supplements in the prevention of the major cardiovascular events in subgroup meta-analysis by various factors. Overall, subgroup meta-analyses by type of supplement (table 2) showed that there was no significant association between vitamin or antioxidant supplements and the risk of the major cardiovascular events (figs 3-6, and table 2), while low dose vitamin B₆ supplementation slightly decreased the risk of major cardiovascular events (relative risk 0.92, 95% confidence interval 0.85 to 0.99; $I^2=35\%$; fig 7) in the fixed effects meta-analysis. Similarly, we found no significant association in the overall subgroup meta-analysis by type of outcome (cardiovascular death, fatal or nonfatal myocardial infarction, stroke, or transient ischaemic attack; table 3), type of prevention (primary v secondary; table 2), type of study design, methodological quality (high v low by score of 5), duration of treatment (<5 years v ≥ 5 years), funding source (independent organisation v pharmaceutical industry) (table 4), and provider of the supplements (pharmaceutical industry v at cost or no mention), while vitamin B₆ and vitamin E supplements were associated with a reduced risk of cardiovascular death (relative

risk 0.91, 95% confidence interval 0.83 to 0.99; $I^2=0\%$) and myocardial infarction (0.77, 0.65 to 0.91; $I^2=76\%$), respectively, and vitamin and antioxidant supplementation marginally increased the risk of angina pectoris (1.04, 1.00 to 1.08; $I^2=36\%$) (table 3⇓).

In the subgroup meta-analysis of high quality randomised controlled trials within each category of low dose vitamin B₆ (relative risk 0.94, 95% confidence interval 0.87 to 1.02; $I^2=39\%$; fixed effects model, table 2⇓ and fig 7⇓) and angina (1.01, 0.86 to 1.18; $I^2=57\%$; random effects model, table 3⇓), however, beneficial or harmful effects disappeared. Also, even though vitamin B₆ supplementation was associated with decreased risks of cardiovascular death in high quality trials, and vitamin E supplementation with a decreased risk of myocardial infarction, those beneficial effects were seen only in trials supplied with supplements by pharmaceutical industry (fig 8⇓ and table 3⇓).

In the subgroup meta-analysis by the number of participants in each trial, vitamin or antioxidant supplements showed a trend toward a decreased (but not significant) risk of major cardiovascular events (relative risk 0.97, 95% confidence interval 0.94 to 1.01; $I^2=40\%$) in the subgroup meta-analysis of trials with <10 000 participants, while those supplements showed an increased (but not significant) risk of the major cardiovascular events (1.02, 0.99 to 1.04; $I^2=39\%$) in the subgroup meta-analysis of those with ≥10 000 participants (table 4⇓).

Table 5⇓ shows the efficacy of vitamin and antioxidant supplements given singly or in combination with other vitamin or antioxidant supplements on major cardiovascular events in subgroup meta-analyses. We found no significant beneficial effect of vitamin and antioxidant supplements in most of the subgroup meta-analyses, while only vitamin E supplements had a marginally significant decreased efficacy for the major cardiovascular events in high quality trials (relative risk 0.95, 95% confidence interval 0.90 to 1.00; $I^2=45\%$).

Discussion

Summary of main findings

In this large scale meta-analysis of randomised controlled trials, we found no evidence to support the use of vitamin or antioxidant supplements for the primary or secondary prevention of major cardiovascular events. Furthermore, these supplements were not associated with any reduced risk of the such events in the subgroup meta-analyses according to various factors such as type of vitamins and antioxidants, type of cardiovascular outcomes, study design, methodological quality, duration of treatment, funding source, provider of supplements, type of control, number of participants in each trial, and supplements given singly or in combination with other vitamins or antioxidant supplements.

Strengths of the current meta-analysis

Our main findings are consistent with those of previous meta-analyses that investigated the association between the use of vitamin B, ^{7 61 62} vitamin D, ⁶³ vitamin E, ^{5 64 65} β carotene, ⁵ folic acid, ^{7 8 61 62 66} or selenium ⁶ and cardiovascular diseases in randomised controlled trials.

Our findings, however, are inconsistent with those of previous in vivo animal studies that suggested vitamins or antioxidants inhibit the development of atherosclerosis ⁶⁷⁻⁷⁰ and in vitro laboratory studies that indicated vitamins and antioxidants reduce lipid peroxidation and free radical damage, and finally inhibit atherosclerosis. ⁷¹⁻⁷³ The findings from animal and

laboratory studies are associated with the oxidative modification hypothesis of atherosclerosis. This hypothesis, which claims that the oxidation of low density lipoprotein cholesterol initiates atherosclerosis, could explain these associations. ⁷⁰ It suggests that accumulated low density lipoprotein in the subendothelial space of arteries is oxidised to minimally modified low density lipoprotein by vascular cells, which then induces accumulation of monocytes and macrophages, which stimulate further peroxidation of low density lipoprotein. ⁷⁴ This reaction makes oxidised low density lipoprotein more negatively charged and completely oxidised. ⁷⁵ The uptake of completely oxidised low density lipoprotein leads to massive uptake of cholesterol by the macrophages. ⁷⁰ It also stimulates the binding of monocytes to the endothelium, promotes the release of lipids and lysosomal enzymes, and thus enhances the progression of atherosclerosis. ^{70 76}

Our meta-analysis indicates that there is a discrepancy in findings between in vivo animal or in vitro laboratory studies and randomised controlled trials with regard to the association between vitamin or antioxidants (natural forms in fruit and vegetables or synthetic forms) and cardiovascular disease. Several theories could explain this discrepancy. Firstly, preclinical studies such as animal studies and in vitro laboratory studies might not represent the biological processes in the human body. ⁷³ Thus, even though vitamins or antioxidant substances show benefits against a certain disease in preclinical studies, they might show no benefit or could be harmful under clinical circumstances. Secondly, the beneficial effects of vitamin or antioxidant supplements might be related to the timing of their administration. For example, the beneficial effects vitamin C occur in the early stages of atherosclerosis, ⁷³ and once the atherosclerotic plaque has developed it has no beneficial effect. ⁷⁷ In the trials we included in our analysis, the mean age of participants ranged from 49 to 82, the ages at which atherosclerotic plaques or changes might be already formed. ⁷³

We found a similar discrepancy in findings between case-control studies and randomised controlled trials. This could be explained by methodological biases of case-control studies. Case-control studies use retrospective assessment of each participant's information on fruit and vegetable consumption and are thus susceptible to two potential biases: recall and selection.

Even though cohort studies are less biased than case-control studies, some important methodological issues might explain the differences in findings between cohort studies and randomised controlled trials. The diet assessment tools such as the food frequency questionnaire might not precisely assess an individual's long term diet or might not provide sufficient information on fruit and vegetable consumption. Also, and more importantly, the use of vitamin or antioxidant supplements in randomised controlled trials should not be seen as equivalent to the intake of fruit and vegetables in cohort studies, which contain other various micronutrients as well as specific nutritional substances. Beneficial effects of vitamin or antioxidant supplements on cardiovascular disease might be obtained from the combination of various nutrients, not from one or several specific nutrients.

Strengths and weaknesses in relation to other meta-analyses

Our findings are similar to those of the previous meta-analysis of randomised controlled trials on the association between vitamin or antioxidant supplementation and other outcomes such as mortality and cancer. In 2007, Bjelakovic et al reported that vitamin A, vitamin E, or β carotene supplements were

associated with increased mortality in a meta-analysis of 47 low bias (high quality) trials with 180 938 participants, while vitamin C and selenium were not associated with mortality.⁷⁸ Regarding the negative effect of antioxidant supplements on mortality, they suggested that the elimination of free radicals in the human body through antioxidant supplementation interferes with essential defensive mechanisms such as apoptosis, phagocytosis, and detoxification and might lead to an increased mortality.⁷⁸ Their updated meta-analysis including the recently published trials had similar findings on this issue and suggested that antioxidant supplements should be considered as medicinal products and should undergo sufficient evaluation before they are marketed.⁷⁹ In 2010, Myung et al reported that antioxidant supplements had no primary or secondary preventive effect on cancer and even increased the risk of bladder cancer in a meta-analysis of 22 randomised controlled trials.⁸⁰

Because of these discrepancies in results between preclinical studies and clinical trials, the findings from preclinical studies on the effects or actions of vitamin or antioxidant substances should not be directly applied to humans.

In the meantime, when we performed subgroup meta-analyses by quality (high v low), dose (low v high), and supplements given singly or in combination with other supplements, we found no overall association between vitamin or antioxidant supplements and the risk of major cardiovascular events, while vitamin and antioxidant supplementation were associated with a marginally increased risk of angina pectoris, and low dose vitamin B₆ supplementation with a slightly decreased risk of major cardiovascular events. In the subgroup meta-analysis of high quality randomised controlled trials within each category, however, beneficial or harmful effects disappeared. We cannot therefore conclude that vitamin and antioxidant supplements are harmful for angina pectoris or that vitamin B₆ supplements are beneficial for major cardiovascular events. Also, even though vitamin B₆ supplementation was associated with a decreased risk of cardiovascular mortality in high quality trials, and vitamin E supplementation was associated with a decreased risk of myocardial infarction, those beneficial effects were shown only in trials with supplements provided by the pharmaceutical industry. So we cannot completely exclude the possibility that this might have influenced the respective trial design, results, or interpretations.

We also found that there was a trend toward an increased (not significant) risk of major cardiovascular events for the supplementation group in subgroup meta-analysis of trials with $\geq 10\,000$ participants, while there was a trend toward a decreased (not significant) risk in subgroup meta-analysis of trials with $<10\,000$ participants. Given that a larger sample size is more accurate than a smaller size, we cannot exclude that vitamin or antioxidant supplementation might be associated with an increase in the risk of cardiovascular disease. Further large scale trials are needed to confirm this.

Weaknesses of the current meta-analysis

There are several limitations in the current study. Firstly, we investigated the association only between synthetic vitamin and antioxidant supplements and cardiovascular disease. Thus, our findings could not be directly applied to fruit and vegetables rich in natural vitamins or antioxidants or natural vitamins derived or extracted from plants. Secondly, we were unable to evaluate whether vitamin and antioxidant supplementation would be beneficial against cardiovascular disease for populations who are deficient in vitamins or antioxidants at baseline. Further randomised controlled trials in those populations are needed.

Thirdly, we used the Jadad scale to assess the methodological quality of the trials, which has been criticised because it is subject to the generic problems of scales, has a strong emphasis on reporting rather than conduct, and does not cover concealment of allocation, one of the important biases in randomised controlled trials.⁸¹ As an alternative, the Cochrane Risk of Bias (RoB) tool has been used to evaluate internal validity of randomised controlled trials since 2008. Hartling et al, however, reported that the inter-rater agreement varied substantially across domains in the Cochrane tool, and it took considerably longer to complete than the Jadad scale.⁸² Further validated tools for the assessment of quality are needed. Finally, we assessed the methodological quality of the trials based only on the data presented in each article. Thus, we might not have assessed the actual performance or biases of each trial.

Meaning of the findings

In summary, we found no evidence to support the use of vitamin or antioxidant supplements in the prevention of cardiovascular disease. Also, recent meta-analyses have shown that vitamin or antioxidant supplements are associated with increased mortality and have no preventive effect on cancer or were even associated with increases in some types of cancer. Most countries permit the pharmaceutical or food industry to sell these supplements under the name of functional food or medical food, and many people take vitamin or antioxidant supplements in the belief that they improve their health. Based on recent meta-analyses of randomised controlled trials, including the current study, however, governments and regulating agencies for food and drugs should consider vitamin and antioxidant supplements as medicinal products and strictly evaluate their efficacy and safety before marketing.

Unanswered questions and future research

Further randomised controlled trials are required to determine whether vitamin and antioxidant supplementation would be beneficial against cardiovascular disease for people who are deficient in vitamins or antioxidants at baseline. Regarding the assessment of methodological quality of each trial, further validated tools that could assess the actual performance or biases of each trial should be developed.

Contributors: BC and S-KM were responsible for the initial plan, study design, conducting the study, data interpretation, and manuscript drafting. S-KM was responsible for statistical analysis. S-KM, WJ, and S-WO were responsible for data collection, data extraction, and data interpretation. SMP, B-KK, and B-J P were responsible for data interpretation and manuscript drafting. BC and S-KM are guarantors.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Not required.

Data sharing: No additional data available.

- 1 Mendis S, Lindholm LH, Anderson SG, Alwan A, Koju R, Onwubere BJ, et al. Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. *J Clin Epidemiol* 2011;64:1451-62.
- 2 Dauchet L, Amouyel P, Dallongeville J. Fruits, vegetables and coronary heart disease. *Nat Rev Cardiol* 2009;6:599-608.

What is already known on this topic

Over the past few decades, observational epidemiological studies have reported that intake of fruit and vegetables rich in various vitamins and antioxidants is associated with a reduced risk of cardiovascular disease

Unlike the evidence for the benefits of fruit and vegetables, however, randomised controlled trials have had inconsistent results regarding benefits of vitamin or antioxidant supplements

Even though several meta-analyses of randomised controlled trials have been published, those involved individual vitamin or antioxidant supplements, and there has been no published comprehensive meta-analysis that reviewed this topic all at once in one report

What this study adds

This large scale meta-analysis of randomised controlled trials suggests that there is no evidence to support the use of vitamin or antioxidant supplements for the primary or secondary prevention of major cardiovascular events

Governments and regulating agencies for food and drug should consider vitamin and antioxidant supplements as medicinal products and strictly evaluate their efficacy and safety before marketing

- 3 Lock K, Pomerleau J, Causser L, Altmann DR, McKee M. The global burden of disease attributable to low consumption of fruit and vegetables: implications for the global strategy on diet. *Bull World Health Organ* 2005;83:100-8.
- 4 Bhupathiraju SN, Tucker KL. Coronary heart disease prevention: nutrients, foods, and dietary patterns. *Clin Chim Acta* 2011;412:1493-514.
- 5 Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. *Lancet* 2003;361:2017-23.
- 6 Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, Guallar E. Selenium and coronary heart disease: a meta-analysis. *Am J Clin Nutr* 2006;84:762-73.
- 7 Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. *Stroke* 2010;41:1205-12.
- 8 Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, et al. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. *Clin J Am Soc Nephrol* 2011;6:482-8.
- 9 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1-12.
- 10 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539-58.
- 11 Korpela H, Kumpulainen J, Jussila E, Kemilä S, Kääriäinen M, Kääriäinen T, et al. Effect of selenium supplementation after acute myocardial infarction. *Res Commun Chem Pathol Pharmacol* 1989;65:249-52.
- 12 Kuklinski B, Weissenbacher E, Fahnrich A. Coenzyme Q10 and antioxidants in acute myocardial infarction. *Mol Aspects Med* 1994;15(suppl):s143-7.
- 13 Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. *Am J Clin Nutr* 1995;62:1381-4S.
- 14 Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 1996;334:1150-5.
- 15 Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet* 1996;347:781-6.
- 16 Mark SD, Wang W, Fraumeni JF Jr, Li JY, Taylor PR, Wang GQ, et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. *Am J Epidemiol* 1996;143:658-64.
- 17 Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 1996;334:1145-9.
- 18 Greenberg ER, Baron JA, Karagas MR, Stukel TA, Nierenberg DW, Stevens MM, et al. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. *JAMA* 1996;275:699-703.
- 19 Rapola JM, Virtamo J, Ripatti S, Huttenen JK, Albanes D, Taylor PR, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. *Lancet* 1997;349:1715-20.
- 20 Virtamo J, Rapola JM, Ripatti S, Heinonen OP, Taylor PR, Albanes D, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. *Arch Intern Med* 1998;158:668-75.
- 21 GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. *Lancet* 1999;354:447-55.
- 22 Komulainen M, Kröger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomised trial. *J Clin Endocrinol Metab* 1999;84:546-52.
- 23 Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. *Lancet* 1999;354:723-9.
- 24 Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342:154-60.
- 25 Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. *Lancet* 2000;356:1213-8.
- 26 Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 2001;345:1583-92.
- 27 De Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. *Lancet* 2001;357:89-95.
- 28 You WC, Chang YS, Heinrich J, Ma JL, Liu WD, Zhang L, et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. *Eur J Cancer Prev* 2001;10:257-63.
- 29 Rafiee P, Shi Y, Kong X, Pritchard KA Jr, Tweddell JS, Litwin SB, et al. Activation of protein kinases in chronically hypoxic infant human and rabbit hearts: role in cardioprotection. *Circulation* 2002;106:239-45.
- 30 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;360:23-33.
- 31 Schnyder G, Roffi M, Flammar Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomised controlled trial. *JAMA* 2002;288:973-9.
- 32 Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomised controlled trial. *JAMA* 2002;288:2432-40.
- 33 Liem A, Reynierse-Buitenwerf GH, Zwiderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. *J Am Coll Cardiol* 2003;41:2105-13.
- 34 Righetti M, Ferrario GM, Milani S, Serbelloni P, La Rosa L, Uccellini M, et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. *Med Sci Monit* 2003;9:PI19-24.
- 35 Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ* 2003;326:469.
- 36 Lange H, Suryapranata H, De Luca G, Börner C, Dille J, Kallmayer K, et al. Folate therapy and in-stent restenosis after coronary stenting. *N Engl J Med* 2004;350:2673-81.
- 37 Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, et al. The SU.VI.MAX Study: a randomised, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. *Arch Intern Med* 2004;164:2335-42.
- 38 Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomised controlled trial. *JAMA* 2004;291:565-75.
- 39 Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomised trial of folic acid for prevention of cardiovascular events in end-stage renal disease. *J Am Soc Nephrol* 2004;15:420-6.
- 40 Brazier M, Grados F, Kamel S, Mathieu M, Morel A, Maamer M, et al. Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomised, double-blind, placebo-controlled study. *Clin Ther* 2005;27:1885-93.
- 41 Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomised controlled trial. *JAMA* 2005;294:56-65.
- 42 Zoungas S, McGrath BP, Brannley P, Kerr PG, Muske C, Wolfe R, et al. Cardiovascular morbidity and mortality in the atherosclerosis and folic acid supplementation trial (ASFAST) in chronic renal failure: a multicenter, randomised, controlled trial. *J Am Coll Cardiol* 2006;47:1108-16.
- 43 Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med* 2006;354:1567-77.
- 44 Børnaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med* 2006;354:1578-88.
- 45 Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, et al. Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomised clinical trial. *Am J Epidemiol* 2006;163:694-9.
- 46 Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomised controlled trial. *JAMA* 2007;298:1163-70.
- 47 Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, et al. Calcium/vitamin D supplementation and cardiovascular events. *Circulation* 2007;115:846-54.
- 48 Berggren M, Stenvall M, Olofsson B, Gustafson Y. Evaluation of a fall-prevention program in older people after femoral neck fracture: a one-year follow-up. *Osteoporos Int* 2008;19:801-9.
- 49 Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. *Arterioscler Thromb Vasc Biol* 2008;28:341-7.
- 50 Prince RL, Austin N, Devine A, Dick IM, Bruce D, Zhu K. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. *Arch Intern Med* 2008;168:103-8.

- 51 Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomised trial. *JAMA* 2008;299:2027-36.
- 52 Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomised controlled trial. *JAMA* 2008;300:795-804.
- 53 Hodis HN, Mack WJ, Dustin L, Maher PR, Azen SP, Detrano R, et al. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomised controlled trial. *Stroke* 2009;40:730-6.
- 54 House AA, Eliasziw M, Catrnan DC, Churchill DN, Oliver MJ, Fine A, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomised controlled trial. *JAMA* 2010;303:1603-9.
- 55 Heinz J, Kropf S, Domröse U, Westphal S, Borucki K, Luley C, et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomised controlled trial. *Circulation* 2010;121:1432-8.
- 56 Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomised trial. *JAMA* 2010;303:2486-94.
- 57 Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. *BMJ* 2010;341:c6273.
- 58 VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITATOPS (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. *Lancet Neurol* 2010;9:855-65.
- 59 Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the folic acid for vascular outcome reduction in transplantation trial. *Circulation* 2011;123:1763-70.
- 60 Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schavartz M, et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomised controlled trial. *JAMA* 2012;308:1751-60.
- 61 Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomised trials involving 37 485 individuals. *Arch Intern Med* 2010;170:1622-31.
- 62 Mei W, Rong Y, Jinming L, Yongjun L, Hui Z. Effect of homocysteine interventions on the risk of cerebrovascular events: a meta-analysis of randomised controlled trials. *Int J Clin Pract* 2010;64:208-15.
- 63 Elamin MB, Abu Elnour NO, Elamin KB, Fatoureh MM, Alkatib AA, Almandoz JP, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2011;96:1931-42.
- 64 Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomised trials of vitamin E in the treatment and prevention of cardiovascular disease. *Arch Intern Med* 2004;164:1552-6.
- 65 Shekelle PG, Morton SC, Jungvig LK, Udani J, Spar M, Tu W, et al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. *J Gen Intern Med* 2004;19:380-9.
- 66 Zhou YH, Tang JY, Wu MJ, Lu J, Wei X, Qin YY, et al. Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis. *PLoS One* 2011;6:e25142.
- 67 Parker RA, Sabrah T, Cap M, Gill BT. Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters. *Arterioscler Thromb Vasc Biol* 1995;15:349-58.
- 68 Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. *Nat Med* 1998;4:1189-92.
- 69 Crawford RS, Kirk EA, Rosenfeld ME, LeBoeuf RC, Chait A. Dietary antioxidants inhibit development of fatty streak lesions in the LDL receptor-deficient mouse. *Arterioscler Thromb Vasc Biol* 1998;18:1506-13.
- 70 Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. *N Engl J Med* 1997;337:408-16.
- 71 Ricciarelli R, Zingg JM, Azzi A. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. *Circulation* 2000;102:82-7.
- 72 Ulrich-Merzenich G, Metzner C, Schiermeyer B, Vetter H. Vitamin C and vitamin E antagonistically modulate human vascular endothelial and smooth muscle cell DNA synthesis and proliferation. *Eur J Nutr* 2002;41:27-34.
- 73 Farbstein D, Kozak-Blickstein A, Levy AP. Antioxidant vitamins and their use in preventing cardiovascular disease. *Molecules* 2010;15:8098-110.
- 74 Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. *Proc Natl Acad Sci U S A* 1987;84:2995-8.
- 75 Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. *Proc Natl Acad Sci U S A* 1981;78:6499-503.
- 76 Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Nerem RM. The pathogenesis of atherosclerosis: an overview. *Clin Cardiol* 1991;14:11-16.
- 77 Aguirre R, May JM. Inflammation in the vascular bed: importance of vitamin C. *Pharmacol Ther* 2008;119:96-103.
- 78 Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomised trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. *JAMA* 2007;297:842-57.
- 79 Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst Rev* 2012;3:CD007176.
- 80 Myung SK, Kim Y, Ju W, Choi HJ, Bae WK. Effects of antioxidant supplements on cancer prevention: meta-analysis of randomised controlled trials. *Ann Oncol* 2010;21:166-79.
- 81 Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.0, February 2008. www.cochrane-handbook.org.
- 82 Hartling L, Ospina M, Liang Y, Dryden DM, Hooton N, Krebs Seida J, et al. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. *BMJ* 2009;339:b4012.
- 83 Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomised controlled trial. *JAMA* 2008;300:2123-33.

Accepted: 19 December 2012

Cite this as: *BMJ* 2013;346:f10

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: <http://creativecommons.org/licenses/by-nc/2.0/> and <http://creativecommons.org/licenses/by-nc/2.0/legalcode>.

Tables

Table 1 | Methodological quality, based on Jadad scale, of 47* included trials on efficacy of vitamin and antioxidant supplements in prevention of cardiovascular diseases

	Randomisation	Description of randomisation methods	Double blind	Used identical placebo	Follow-up reporting	Total score
Steiner, 1995 ¹³	1	0	1	1	1	4
Omenn, 1996 (CARET) ¹⁴	1	1	1	1	1	5
Stephens, 1996 (CHAOS) ¹⁵	1	1	1	1	1	5
Mark, 1996 (LNIT) ¹⁶	1	1	1	1	0	4
Hennekens, 1996 (PHS) ¹⁷	1	0	1	1	1	4
Greenberg, 1996 (SCP) ¹⁸	1	1	1	1	1	5
Rapola, 1997 (ATBC) ¹⁹	1	1	1	1	1	5
Virtamo, 1998 (ATBC) ²⁰	1	1	1	1	1	5
GISSI, 1999 ²¹	1	1	0	0	1	3
Komulainen, 1999 (KOS) ²²	1	0	1	1	1	4
Green, 1999 (NSCP) ²³	1	0	0	1	1	3
Yusuf, 2000 (HOPE) ²⁴	1	0	1	1	0	3
Boaz, 2000 (SPACE) ²⁵	1	1	1	1	0	4
Brown, 2001 (HATS) ²⁶	1	0	1	1	1	4
De Gaetano, 2001 (PPP) ²⁷	1	1	0	0	1	3
You, 2001 ²⁸	1	0	1	1	1	4
HPS, 2002 ³⁰	1	1	0	1	1	4
Schnyder, 2002 (SHS) ³¹	1	0	1	1	1	4
Waters, 2002 (WAVE) ³²	1	1	1	1	1	5
Liem, 2003 (Goes) ³³	1	1	0	0	1	3
Righetti, 2003 ³⁴	1	1	0	0	1	3
Trivedi, 2003 ³⁵	1	0	1	1	1	4
Lange, 2004 ³⁶	1	0	1	1	1	4
Hercberg, 2004 (SU.VI.MAX) ³⁷	1	1	1	1	1	5
Toole, 2004 (VISP) ³⁸	1	1	1	1	1	5
Wrone, 2004 ³⁹	1	1	1	1	1	5
Brazier, 2005 ⁴⁰	1	1	1	1	1	5
Lee, 2005 (WHS) ⁴¹	1	1	1	1	1	5
Zoungas, 2006 (ASFAST) ⁴²	1	0	1	1	1	4
Lonn, 2006 (HOPE-2) ⁴³	1	1	1	1	1	5
Bønaa, 2006 (NORVIT) ⁴⁴	1	1	1	1	1	5
Stranges, 2006 (NPC) ⁴⁵	1	1	1	1	0	4
Jamison, 2007 (HOST) ⁴⁶	1	1	1	1	1	5
Hsia, 2007 (WHI) ⁴⁷	1	0	1	1	0	3
Berggren, 2008 ⁴⁸	1	0	0	0	1	2
Milman, 2008 (ICARE) ⁴⁹	1	1	1	1	1	5
Prince, 2008 ⁵⁰	1	1	1	1	1	5
Albert, 2008 (WAFACS) ⁵¹	1	0	1	1	1	4
Ebbing, 2008 (WENBIT) ⁵²	1	1	1	1	1	5
Hodis, 2009 (BVAIT) ⁵³	1	1	1	1	1	5
House, 2010 (DIVINE) ⁵⁴	1	1	1	1	1	5
Heinz, 2010 ⁵⁵	1	0	1	1	1	4
Armitage, 2010 (SEARCH) ⁵⁶	1	1	1	1	1	5
Galan, 2010 (SU.FOL.OM3) ⁵⁷	1	1	1	1	1	5

Table 1 (continued)

	Randomisation	Description of randomisation methods	Double blind	Used identical placebo	Follow-up reporting	Total score
VITATOPS 2010 ⁵⁸	1	1	1	1	1	5
Bostom, 2011 (FAVORIT) ⁵⁹	1	1	1	1	1	5
Sesso, 2012 (PHS2) ⁶⁰	1	1	1	1	1	5

*We were unable to retrieve full text from three trials: Korpela et al, 1989,¹¹ Kuklinski et al, 1994,¹² and Rafiee et al, 2002.²⁹

Table 2| Efficacy of vitamin and antioxidant supplements in the prevention of the major cardiovascular events in subgroup meta-analysis by type of prevention and type of supplement

Factor	No of trials	Relative risk (95% CI)	Heterogeneity I ² (%)	Model
All	50	1.00 (0.98 to 1.02)	42	Fixed effects
Prevention:				
Primary	30	1.01 (0.98 to 1.03)	42	Fixed effects
Secondary	20	1.00 (0.97 to 1.03)	44	Fixed effects
Type of supplement:				
Vitamins only	39	0.99 (0.97 to 1.01)	44	Fixed effects
Low quality trials	17	0.99 (0.96 to 1.02)	32	Fixed effects
High quality trials	22	0.99 (0.94 to 1.05)	53	Random effects
Antioxidants only	22	0.98 (0.96 to 1.02)	41	Fixed effects
Low quality trials	11	0.99 (0.96 to 1.03)	25	Fixed effects
High quality trial	9	0.97 (0.91 to 1.02)	49	Fixed effects
Vitamin A	2	0.98 (0.45 to 2.16)	87	Random effects
Low dose (10 000 IU/day)	1	0.63 (0.37 to 1.07)	NA	NA
High dose (25 000 IU/day)	1	1.41 (1.15 to 1.73)*	NA	NA
Vitamin B ₆	16	0.96 (0.92 to 1.01)	33	Fixed effects
Low dose (3-25 mg/day)	8	0.92 (0.85 to 0.99)*	35	Fixed effects
Low quality trials	3	0.76 (0.61 to 0.94)*	0	Fixed effects
High quality trials	5	0.94 (0.87 to 1.02)	39	Fixed effects
High dose (40-100 mg/day)	8	0.99 (0.94 to 1.05)	22	Fixed effects
Vitamin B ₁₂	17	0.99 (0.95 to 1.02)	37	Fixed effects
Low dose (6 µg-0.5 mg/day)	11	0.96 (0.90 to 1.02)	34	Fixed effects
High dose (1-2 mg/day)	6	1.00 (0.96 to 1.05)	43	Fixed effects
Folic acid	21	0.99 (0.95 to 1.02)	35	Fixed effects
Low dose (500 µg-5 mg/day)	17	0.99 (0.96 to 1.03)	39	Fixed effects
High dose (10-40 mg/day)	4	0.89 (0.78 to 1.03)	0	Fixed effects
Vitamin C†	7	0.99 (0.94 to 1.04)	16	Fixed effects
Low dose (120-250 mg/day)	3	0.99 (0.94 to 1.04)	31	Fixed effects
High dose (500-1000 mg/day)	4	0.98 (0.94 to 1.12)	28	Fixed effects
Vitamin D	7	1.02 (0.98 to 1.07)	23	Fixed effects
Low dose (120-250 mg/day)	2	1.05 (0.99 to 1.12)	0	Fixed effects
High dose (500-1000 mg/day)	5	0.94 (0.86 to 1.03)	0	Fixed effects
Vitamin E†	17	0.97 (0.94 to 1.01)	44	Fixed effects
Low dose (60 IU-250 mg/day)	13	0.96 (0.92 to 1.01)	35	Fixed effects
High dose (500-600 mg/day)	4	0.84 (0.52 to 1.35)	69	Random effects
β carotene	11	1.04 (0.96 to 1.12)	55	Random effects
Low dose (6-25 mg/day)	6	0.99 (0.95 to 1.03)	7	Fixed effects
High dose (30-50 mg/day)	5	1.14 (0.96 to 1.35)	69	Random effects
Selenium	7	0.91 (0.77 to 1.06)	47	Fixed effects
Low dose (50-100 µg/day)	5	0.85 (0.70 to 1.04)	44	Fixed effects
High dose (122-200 µg /day)	2	0.57 (0.10 to 3.16)	67	Fixed effects

NA=not applicable.

*P≤0.05.

†For subgroup meta-analysis of vitamin C and vitamin E, we used data from 2008 PHS2 article⁸³ because data were not available in 2012 PHS article.

Table 3| Efficacy of vitamin and antioxidant supplements in prevention of major cardiovascular events in subgroup meta-analysis by outcome

	No of trials	Relative risk (95% CI)	Heterogeneity I ² (%)	Model
Cardiovascular death	32	1.01 (0.97 to 1.05)	41	Fixed effects
Vitamin A	2	0.98 (0.45 to 2.16)	87	Random effects
Vitamin B ₆	8	0.91 (0.83 to 0.99)*	0	Fixed effects
Low quality trials	4	0.93 (0.75 to 1.14)	12	Fixed effects
High quality trials	4	0.90 (0.82 to 0.99)*	0	Fixed effects
Not supplied by pharmaceutical industry	2	0.96 (0.84 to 1.10)	0	Fixed effects
Supplied by pharmaceutical industry	2	0.85 (0.75 to 0.97)*	0	Fixed effects
Not supplied by pharmaceutical industry	3	0.96 (0.83 to 1.10)	0	Fixed effects
Supplied by pharmaceutical industry	5	0.88 (0.79 to 0.98)*	0	Fixed effects
Vitamin B ₁₂	9	0.96 (0.90 to 1.03)	27	Fixed effects
Folic acid	11	0.96 (0.89 to 1.03)	11	Fixed effects
Vitamin C†	6	1.03 (0.95 to 1.12)	27	Fixed effects
Vitamin D	3	0.90 (0.76 to 1.07)	27	Fixed effects
Vitamin E†	15	0.98 (0.92 to 1.04)	37	Fixed effects
β carotene	10	1.10 (0.96 to 1.27)	61	Random effects
Selenium	15	0.98 (0.92 to 1.04)	37	Fixed effects
Vitamin	2	0.98 (0.45 to 2.16)	87	Random effects
Angina	10	1.04 (1.00 to 1.08)*	36	Fixed effects
Low quality trials	6	1.05 (1.00 to 1.09)*	25	Fixed effects
High quality trials	4	1.01 (0.86 to 1.18)	57	Random effects
Vitamin B ₆	4	0.93 (0.72 to 1.20)	77	Random effects
Vitamin B ₁₂	4	0.93 (0.72 to 1.20)	77	Random effects
Folic acid	4	0.93 (0.72 to 1.20)	77	Random effects
Vitamin C†	2	0.94 (0.85 to 1.03)	0	Fixed effects
Vitamin D	1	1.07 (0.93 to 1.23)	NA	NA
Vitamin E†	3	1.15 (0.99 to 1.33)	0	Fixed effects
Myocardial infarction	34	1.00 (0.96 to 1.03)	0	Fixed effects
Vitamin B ₆	13	0.99 (0.91 to 1.07)	11	Fixed effects
Vitamin B ₁₂	14	0.99 (0.93 to 1.06)	4	Fixed effects
Folic acid	15	0.99 (0.93 to 1.06)	0	Fixed effects
Vitamin C†	4	0.96 (0.87 to 1.07)	0	Fixed effects
Vitamin D	2	1.06 (0.92 to 1.21)	0	Fixed effects
Vitamin E†	12	0.77 (0.65 to 0.91)*	76	Random effects
Low quality trials	5	0.76 (0.57 to 1.01)	81	Random effects
High quality trials	7	0.75 (0.58 to 0.97)*	75	Random effects
Not supplied by pharmaceutical industry	4	0.79 (0.53 to 1.17)	62	Random effects
Supplied by pharmaceutical industry	3	0.67 (0.42 to 1.07)*	86	Random effects
Primary prevention	7	0.72 (0.54 to 0.95)*	76	Random effects
Not supplied by pharmaceutical industry	3	0.79 (0.42 to 1.50)	55	Random effects
Supplied by pharmaceutical industry	4	0.63 (0.42 to 0.97)*	82	Random effects
Secondary prevention	5	0.79 (0.61 to 1.02)	80	Random effects
Not supplied by pharmaceutical industry	4	0.79 (0.53 to 1.17)	62	Random effects
Supplied by pharmaceutical industry	8	0.73 (0.59 to 0.92)*	82	Random effects
β carotene	4	0.95 (0.80 to 1.14)	52	Random effects
Selenium	3	0.87 (0.59 to 1.28)	0	Fixed effects
Fatal myocardial infarction	9	1.02 (0.92 to 1.12)	43	Fixed effects
Vitamin B ₆	1	1.00 (0.75 to 1.33)	NA	NA
Vitamin B ₁₂	1	1.00 (0.75 to 1.33)	NA	NA

Table 3 (continued)

	No of trials	Relative risk (95% CI)	Heterogeneity I ² (%)	Model
Folic acid	1	1.00 (0.75 to 1.33)	NA	NA
Vitamin E†	3	0.57 (0.32 to 1.03)	0	Fixed effects
β carotene	1	1.05 (0.95 to 1.17)	NA	NA
Selenium	1	1.12 (0.43 to 2.87)	NA	NA
Non-fatal myocardial infarction	13	0.83 (0.66 to 1.04)	89	Random effects
Vitamin B ₆	3	1.08 (0.90 to 1.30)	22	Fixed effects
Vitamin B ₁₂	4	1.03 (0.93 to 1.14)	1	Fixed effects
Folic acid	4	1.03 (0.93 to 1.14)	1	Fixed effects
Vitamin C†	4	0.85 (0.70 to 1.04)	0	Random effects
Vitamin E†	9	0.57 (0.32 to 1.03)	0	Fixed effects
β carotene	4	0.95 (0.80 to 1.14)	52	Random effects
Selenium	3	0.82 (0.53 to 1.27)	0	Fixed effects
Stroke	32	0.97 (0.93 to 1.02)	0	Fixed effects
Vitamin B ₆	12	0.93 (0.85 to 1.01)	13	Fixed effects
Vitamin B ₁₂	5	0.91 (0.80 to 1.03)	8	Fixed effects
Folic acid	7	0.90 (0.79 to 1.01)	19	Fixed effects
Vitamin C†	4	0.98 (0.88 to 1.09)	0	Fixed effects
Vitamin D	5	1.00 (0.88 to 1.13)	6	Fixed effects
Vitamin E†	12	1.00 (0.93 to 1.09)	20	Fixed effects
β carotene	2	0.98 (0.89 to 1.07)	0	Fixed effects
Selenium	1	1.09 (0.68 to 1.72)	NA	NA
Transient ischaemic attack	5	1.12 (0.97 to 1.30)	0	Fixed effects
Vitamin B ₆	2	1.12 (0.88 to 1.42)	0	Fixed effects
Vitamin B ₁₂	2	1.12 (0.88 to 1.42)	0	Fixed effects
Folic acid	2	1.12 (0.88 to 1.42)	0	Fixed effects
Vitamin D	1	1.12 (0.96 to 1.42)	NA	NA
Vitamin E†	2	0.93 (0.59 to 1.47)	0	Fixed effects

NA=not applicable.

*P≤0.05.

†For subgroup meta-analysis of vitamin C and vitamin E, we used data from 2008 PHS2 article⁸³ because data were not available in 2012 PHS article.

Table 4| Efficacy of vitamin and antioxidant supplements in prevention of major cardiovascular events in subgroup meta-analysis by various factors

Factor	No of trials	Relative risk (95% CI)	Heterogeneity, I^2 (%)	Model
Study design:				
RDBPCT	45	1.00 (0.98 to 1.02)	46	Fixed effects
OLRCT	5	0.98 (0.89 to 1.07)	0	Fixed effects
Methodological quality:				
High quality (Jadad score 5)	24	0.99 (0.96 to 1.03)	45	Fixed effects
Low quality (Jadad score ≤ 4)	23	1.01 (0.98 to 1.03)	32	Fixed effects
Duration of treatment (years):				
<5	34	0.97 (0.90 to 1.04)	52	Random effects
≥ 5	16	1.01 (0.98 to 1.03)	0	Fixed effects
Funding source:				
Pharmaceutical industry	5	1.01 (0.96 to 1.07)	0	Fixed effects
Independent organisation	42	1.00 (0.98 to 1.02)	42	Fixed effects
Supply source for supplements:				
Pharmaceutical industry	29	0.99 (0.97 to 1.02)	33	Fixed effects
Not pharmaceutical industry	18	1.01 (0.98 to 1.05)	47	Fixed effects
Type of control:				
Placebo	44	1.00 (0.98 to 1.02)	46	Fixed effects
No placebo	6	0.97 (0.89 to 1.06)	0	Fixed effects
No of participants in each trial:				
<10 000	40	0.97 (0.94 to 1.01)	40	Fixed effects
$\geq 10 000$	10	1.02 (0.99 to 1.04)	39	Fixed effects

RDBPCT=randomised, double blind, placebo-controlled trial; OLRCT=open label, randomised controlled trial.

Table 5| Efficacy of vitamin and antioxidant supplements given singly or combined with other vitamin or antioxidant supplements in prevention of major cardiovascular events in subgroup meta-analysis

Factor	No of trials	Relative risk (95% CI)	Heterogeneity, I ² (%)	Model
All	50	1.00 (0.98 to 1.02)	42	Fixed effects
Vitamin A:				
Given singly	NA	—	—	—
Combined with others	2	0.98 (0.45 to 2.16)	87	Random effects
Vitamin B ₆ :				
Given singly	NA	—	—	—
Combined with others	16	0.96 (0.92 to 1.01)	33	Fixed effects
Low quality trials	5	0.94 (0.73 to 1.21)	66	Random effects
High quality trials	11	0.96 (0.91 to 1.01)	1	Fixed effects
Vitamin B ₁₂ :				
Given singly	NA	—	—	—
Combined with others	17	0.99 (0.95 to 1.02)	37	Fixed effects
Low quality trials	5	0.94 (0.73 to 1.21)	66	Random effects
High quality trials	12	0.98 (0.95 to 1.02)	18	Fixed effects
Folic acid:				
Given singly	4	1.02 (0.84 to 1.23)	47	Fixed effects
Combined with others	17	0.99 (0.95 to 1.02)	37	Fixed effects
Given singly or combined	21	0.99 (0.95 to 1.02)	35	Fixed effects
Low quality trials	8	0.99 (0.90 to 1.08)	49	Fixed effects
High quality trials	12	0.98 (0.95 to 1.02)	18	Fixed effects
Vitamin C*:				
Given singly	NA	—	—	—
Combined with others	7	0.99 (0.94 to 1.06)	16	Fixed effects
Low quality trials	4	0.99 (0.94 to 1.04)	44	Fixed effects
High quality trials	3	0.99 (0.88 to 1.11)	0	Fixed effects
Vitamin D				
Given singly	2	0.95 (0.86 to 1.05)	11	Fixed effects
Combined with others	5	1.04 (0.99 to 1.10)	0	Fixed effects
Given singly or combined	7	1.02 (0.98 to 1.07)	23	Fixed effects
Low quality trials	5	1.02 (0.98 to 1.08)	47	Fixed effects
High quality trials	2	1.01 (0.45 to 2.27)	0	Fixed effects
Vitamin E*:				
Given singly	10	0.93 (0.85 to 1.01)	57	Random effects
Combined with others	7	0.99 (0.94 to 1.04)	15	Fixed effects
Given singly or combined	17	0.97 (0.94 to 1.01)	44	Fixed effects
Low quality trials	9	0.99 (0.95 to 1.03)	43	Fixed effects
High quality trials	8	0.95 (0.90 to 1.00)†	45	Fixed effects
β carotene:				
Given singly	5	1.02 (0.96 to 1.08)	31	Fixed effects
Combined with others	6	1.00 (0.81 to 1.23)	70	Random effects
Given singly or combined	11	1.04 (0.96 to 1.12)	55	Random effects
Low quality trials	6	0.99 (0.95 to 1.03)	30	Fixed effects
High quality trials	5	1.13 (0.98 to 1.29)	64	Random effects
Selenium:				
Given singly	3	0.34 (0.06 to 2.05)	70	Random effects
Combined with others	4	0.88 (0.72 to 1.08)	26	Fixed effects
Given singly or combined	7	0.91 (0.77 to 1.06)	47	Fixed effects
Low quality trials	4	0.91 (0.73 to 1.12)	43	Fixed effects

Table 5 (continued)

Factor	No of trials	Relative risk (95% CI)	Heterogeneity, I ² (%)	Model
High quality trials	1	0.98 (0.77 to 1.24)	NA	NA

NA=not applicable.
*For subgroup meta-analysis of vitamin C and vitamin E, we used data from 2008 PHS2 article⁸³ because data were not available in 2012 PHS article.
†P≤0.05.

Figures

Fig 1 Flow diagram for identification of relevant clinical trials examining effect of vitamins and supplements in prevention of cardiovascular disease

Fig 2 Efficacy of vitamin and antioxidant supplements in prevention of major cardiovascular events in meta-analysis of 50 randomised controlled trials sorted in ascending order of number of participants

Fig 3 Efficacy of vitamin A supplements in prevention of major cardiovascular events in subgroup meta-analysis of randomised controlled trials

Fig 4 Efficacy of vitamins B₆ and B₁₂ and folic acid supplements in prevention of major cardiovascular events in subgroup meta-analysis of randomised controlled trials

Fig 5 Efficacy of vitamins C, D, and E supplements in prevention of major cardiovascular events in subgroup meta-analysis of randomised controlled trials. For subgroup meta-analysis of vitamin C and vitamin E, we used data from 2008 PHS2 article⁸³ because data were not available in 2012 PHS article

Fig 6 Efficacy of β carotene and selenium supplements in prevention of major cardiovascular events in subgroup meta-analysis of randomised controlled trials

Fig 7 Efficacy of low dose vitamin B₆ supplements in prevention of major cardiovascular events in subgroup meta-analysis of randomised controlled trials by study quality according to Jadad scale

Fig 8 Efficacy of vitamin E supplements in prevention of myocardial infarction in subgroup meta-analysis of randomised controlled trials according to provider of supplements (pharmaceutical industry or other). For subgroup meta-analysis of vitamin E, we used data from 2008 PHS2 article⁸³ because data were not available in 2012 PHS article